journal article·2025-10Open access

In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation

Yiru Shi, Yuxuan Hou, Moustafa T. Mabrouk, Chengzhong Yu, Yannan Yang

Advanced Science· Volume 12· Issue 37

Abstract

Abstract Historically, directly injecting therapeutics into tumors has been deemed suboptimal and less favorable in clinical settings compared to systemic administration due to the inability to eradicate circulating/metastatic tumor cells until the emergence of the concept of in situ vaccine. In situ vaccine leverages patients’ own tumors as a pool of antigens to elicit systemic antitumor immunity (also known as “abscopal effect”) that aims to eliminate both primary and distal/metastatic tumors. One typical example of an approved product is Talimogene laherparepvec, an oncolytic virus approved in 2015 for treating advanced melanoma. To improve the effectiveness and the biosafety of in situ vaccines, various approaches have emerged, including new generations of oncolytic viruses, engineered bacteria, cytokine treatment, immune adjuvants, nanotechnology‐enabled formulations, and photo/radio‐therapies, showing remarkable promise in preclinical and clinical settings. These conceptual advances offer tailored solutions to challenges such as low antigen availability, limited immune activation, and side effects. In this review, we explore the current landscape of in situ cancer vaccines, categorizing them based on their functional formulations and highlighting their conceptual innovation in cancer immunotherapy. Additionally, a comprehensive discussion is provided of the existing clinical trials and our perspective on future clinical translation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Cancer Research and Treatments · CAR-T cell therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

South Australian ImmunoGENomics Cancer Institute The University of Adelaide Adelaide SA 5005 Australia

Australian Institute for Bioengineering and Nanotechnology The University of Queensland Brisbane QLD 4072 Australia

References (100+)

Show source-provided references
1. 10.1038/s41571-021-00473-510.1038/s41571-021-00473-5 ↗
2. 10.1158/0008-5472.CAN-17-049110.1158/0008-5472.CAN-17-0491 ↗
3. 10.1038/nri274410.1038/nri2744 ↗
4. 10.1038/nrc235510.1038/nrc2355 ↗
5. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
6. 10.1038/s41423-020-0488-610.1038/s41423-020-0488-6 ↗
7. 10.1002/wnan.152410.1002/wnan.1524 ↗
8. 10.1002/cam4.569810.1002/cam4.5698 ↗
9. 10.1038/s41392-023-01460-110.1038/s41392-023-01460-1 ↗
10. 10.1038/s41392-017-0004-310.1038/s41392-017-0004-3 ↗
11. 10.1002/cam4.214810.1002/cam4.2148 ↗
12. 10.1038/s41573-024-00974-910.1038/s41573-024-00974-9 ↗
13. 10.1038/s41591-019-0498-z10.1038/s41591-019-0498-z ↗
14. 10.1038/s12276-019-0297-010.1038/s12276-019-0297-0 ↗
15. 10.1021/acs.nanolett.7b0010710.1021/acs.nanolett.7b00107 ↗
16. 10.3389/fimmu.2023.130889010.3389/fimmu.2023.1308890 ↗
17. 10.1016/j.ijpharm.2024.12395510.1016/j.ijpharm.2024.123955 ↗
18. 10.1038/s41551-018-0236-810.1038/s41551-018-0236-8 ↗
19. 10.1126/scitranslmed.300898210.1126/scitranslmed.3008982 ↗
20. 10.1021/acscentsci.4c0057910.1021/acscentsci.4c00579 ↗
21. 10.1016/j.chempr.2021.11.02010.1016/j.chempr.2021.11.020 ↗
22. 10.1016/j.biomaterials.2022.12170610.1016/j.biomaterials.2022.121706 ↗
23. 10.1002/adma.20221045210.1002/adma.202210452 ↗
24. McCarthy E. F. · Iowa Orthop. J. · 2006 · 26 · 154
25. 10.1155/2016/845172810.1155/2016/8451728 ↗
26. 10.1001/jamaoncol.2016.206410.1001/jamaoncol.2016.2064 ↗
27. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
28. 10.1038/s41392-023-01407-610.1038/s41392-023-01407-6 ↗
29. 10.1016/j.tranon.2019.10.00110.1016/j.tranon.2019.10.001 ↗
30. 10.1021/acsnano.2c0968510.1021/acsnano.2c09685 ↗
31. 10.1002/cam4.728710.1002/cam4.7287 ↗
32. 10.1038/s41573-024-00974-910.1038/s41573-024-00974-9 ↗
33. 10.1016/j.nantod.2024.10228610.1016/j.nantod.2024.102286 ↗
34. 10.1016/j.ijrobp.2020.08.02310.1016/j.ijrobp.2020.08.023 ↗
35. 10.1038/ncomms1434010.1038/ncomms14340 ↗
36. 10.1080/2162402X.2015.110542910.1080/2162402X.2015.1105429 ↗
37. 10.1158/0008-5472.CAN-19-206210.1158/0008-5472.CAN-19-2062 ↗
38. 10.1016/j.omto.2021.02.00610.1016/j.omto.2021.02.006 ↗
39. 10.1038/s41392-023-01683-210.1038/s41392-023-01683-2 ↗
40. 10.1038/s41467-019-13744-810.1038/s41467-019-13744-8 ↗
41. 10.1021/acsami.2c1680610.1021/acsami.2c16806 ↗
42. 10.3389/fimmu.2024.150663210.3389/fimmu.2024.1506632 ↗
43. 10.3389/fimmu.2024.149246410.3389/fimmu.2024.1492464 ↗
44. 10.1126/scitranslmed.aat914310.1126/scitranslmed.aat9143 ↗
45. 10.1126/scitranslmed.aaw261410.1126/scitranslmed.aaw2614 ↗
46. 10.1038/s41551-021-00831-910.1038/s41551-021-00831-9 ↗
47. 10.1038/s41565-022-01245-710.1038/s41565-022-01245-7 ↗
48. 10.1126/scitranslmed.aan448810.1126/scitranslmed.aan4488 ↗
49. 10.1080/2162402X.2023.229090010.1080/2162402X.2023.2290900 ↗
50. 10.1038/s41467-020-14906-910.1038/s41467-020-14906-9 ↗
51. 10.1016/j.biomaterials.2024.12287010.1016/j.biomaterials.2024.122870 ↗
52. 10.1126/sciadv.adc943610.1126/sciadv.adc9436 ↗
53. 10.1038/s41586-024-08033-410.1038/s41586-024-08033-4 ↗
54. 10.1038/s41467-020-16602-010.1038/s41467-020-16602-0 ↗
55. 10.1038/s41586-021-04003-210.1038/s41586-021-04003-2 ↗
56. 10.1021/acsnano.3c0036310.1021/acsnano.3c00363 ↗
57. 10.1021/acsnano.3c0191210.1021/acsnano.3c01912 ↗
58. 10.1038/s41467-024-48032-710.1038/s41467-024-48032-7 ↗
59. 10.3389/fimmu.2022.96967810.3389/fimmu.2022.969678 ↗
60. 10.1038/s41467-023-37217-110.1038/s41467-023-37217-1 ↗
61. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
62. 10.1038/s41551-020-0597-710.1038/s41551-020-0597-7 ↗
63. 10.1126/sciadv.adn300210.1126/sciadv.adn3002 ↗
64. 10.1111/j.1365-2567.2005.02258.x10.1111/j.1365-2567.2005.02258.x ↗
65. 10.1158/1078-0432.CCR-18-046910.1158/1078-0432.CCR-18-0469 ↗
66. 10.1038/s41467-021-22311-z10.1038/s41467-021-22311-z ↗
67. 10.1002/adma.20210062810.1002/adma.202100628 ↗
68. 10.3390/pharmaceutics1409190810.3390/pharmaceutics14091908 ↗
69. 10.1021/acsami.1c0828510.1021/acsami.1c08285 ↗
70. 10.1186/s12951-021-00865-w10.1186/s12951-021-00865-w ↗
71. 10.1016/j.chempr.2024.08.02010.1016/j.chempr.2024.08.020 ↗
72. 10.1002/adma.20190405810.1002/adma.201904058 ↗
73. 10.1002/anie.20220490410.1002/anie.202204904 ↗
74. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
75. 10.1126/sciadv.abb271210.1126/sciadv.abb2712 ↗
76. 10.1002/adma.20240719910.1002/adma.202407199 ↗
77. 10.1126/scitranslmed.adk064210.1126/scitranslmed.adk0642 ↗
78. 10.1038/s41467-018-04703-w10.1038/s41467-018-04703-w ↗
79. 10.1038/nbt.228710.1038/nbt.2287 ↗
80. 10.1038/nrd466310.1038/nrd4663 ↗
81. 10.1186/s12935-024-03424-z10.1186/s12935-024-03424-z ↗
82. 10.1172/JCI12228710.1172/JCI122287 ↗
83. 10.1038/s41467-020-15229-510.1038/s41467-020-15229-5 ↗
84. Dmitriy Zamarin R. B. H. · Sci. Transl. Med. · 2014 · 6
85. 10.3389/fimmu.2023.132474410.3389/fimmu.2023.1324744 ↗
86. 10.1038/nm.308910.1038/nm.3089 ↗
87. 10.1136/jitc-2019-00041510.1136/jitc-2019-000415 ↗
88. 10.1007/s12672-025-02198-810.1007/s12672-025-02198-8 ↗
89. 10.1126/science.aar406010.1126/science.aar4060 ↗
90. 10.1038/nature1067310.1038/nature10673 ↗
91. 10.1038/s41571-021-00588-910.1038/s41571-021-00588-9 ↗
92. 10.1038/s41416-018-0328-y10.1038/s41416-018-0328-y ↗
93. 10.1038/s41523-023-00508-310.1038/s41523-023-00508-3 ↗
94. 10.1007/s00262-014-1523-110.1007/s00262-014-1523-1 ↗
95. 10.1158/1078-0432.CCR-11-048210.1158/1078-0432.CCR-11-0482 ↗
96. 10.1002/ijc.2375610.1002/ijc.23756 ↗
97. 10.3389/fimmu.2020.57559710.3389/fimmu.2020.575597 ↗
98. 10.1158/2326-6066.CIR-23-063610.1158/2326-6066.CIR-23-0636 ↗
99. 10.1093/pnasnexus/pgac24410.1093/pnasnexus/pgac244 ↗
100. 10.1007/s13277-013-1511-710.1007/s13277-013-1511-7 ↗